New combo therapy targets tough pancreatic tumors
NCT ID NCT07386704
First seen Feb 04, 2026 · Last updated May 07, 2026 · Updated 14 times
Summary
This study is testing whether adding the drug nimotuzumab to standard chemotherapy and radiation can help control pancreatic cancer that has spread only a little or is too advanced for surgery. About 30 adults with this type of cancer will receive the combination treatment. The main goal is to see if the tumor stays under control for at least one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Radiotherapy Oncology, Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Conditions
Explore the condition pages connected to this study.